anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A pharmaceutical composition for treatment of metabolic diseases including a blood-born hemosphere (BBHS) is provided to be able to be used as medicine for metabolic diseases by inducing differentiation of BBHS to an insulin-secreting cell. CONSTITUTION: A pharmaceutical composition for treatment of metabolic diseases includes BBHS. The BBHS is formed by isolating monocytic cells from human blood and performing the three dimensional aggregation cultivation. The BBHS is induced to an insulin-secreting cell. The metabolic diseases are selected from a group consisting of diabetes, hyperlipidemia, and obesity. A method of curing metabolic diseases administers the pharmaceutically effective dose of the pharmaceutical composition to an individual.
Physical inactivity and increased caloric intake play important roles in the pathophysiology of obesity. Increases of physical activity and modifications of eating behaviors are first-line interventions which, however, are not easily implemented, and lack of time to exercise and difficulties in coping with different diets are common reasons for failure. High-intensity interval training (HIIT) is a "faster" alternative to moderate-intensity continuous training (CT). Conversely, intermittent fasting is also an alternative to more complex diets, as it restricts caloric intake to a specified period of time without major diet composition changes. The combination of HIIT and fasting may therefore provide incremental benefits.

Sedentary women aged ≥ 30 years and ≤50 years, with body mass index ≥25 kg/m2 and cardiometabolic risk factors, will be randomized to HIIT performed in the fasting state, HIIT performed in the fed state, CT in the fasting state or CT in the fed state. Cardiometabolic parameters, anthropometric indices, cardiorespiratory fitness, quality of life and microvascular function (cutaneous capillary density and microvascular reactivity evaluated by laser speckle contrast imaging) will be evaluated before the initiation of the interventions and 4 weeks thereafter.
Bortezomib 1.3mg/m2 to assess efficacy in low prior anthracycline exposure. Patients receive idarubicin IV (12 mg/m2/day) over 15 minutes on days 1-3, low-dose cytarabine IV (100 mg/m2/day) continuously over days 1-7, and bortezomib IV (1.3 mg/m2) on days 1, 4, and 8. All patients receive intrathecal cytarabine (30 mg - age 1-1.99 years, 50 mg - age 2-2.99 years, 70 mg - age ≥ 3 years) prior to courses 1 and 2. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity (closed as of 08/01/10). Dosage modification based on age \< 3 years old.
Cadmium (Cd) plays a key role in the occurrence of myocardial infarction (MI). We aimed to explore the association between blood Cd levels and all-cause mortality of MI on the basis of the National Health and Nutrition Examination Survey databases. This study included 800 adults with MI to obtain blood Cd concentrations and their follow-up information. The association between Cd concentrations and mortality was analyzed using Cox regression, restricted cubic spline (RCS) models, mediation analysis, receiver operating characteristic curve, and Kaplan-Meier curves. All the patients were divided into 4 groups according to the quartiles of blood Cd levels (Q1, Q2, Q3, and Q4). Cox regression analysis with adjustment for covariates indicated that Cd was the promoting factor of mortality, and patients with higher Cd had a higher death risk. The RCS model indicated an "inverted checkmark" shaped correlation between Cd levels and mortality, and a turning point of 1.06 μg/L was found. A significant positive correlation was observed on the left of the turning point. Grouped patients by turning point into 2 groups, Kaplan-Meier analysis showed that the low-concentration group had a lower death risk than the high-concentration group. Subgroup analysis revealed that the prognostic effect of Cd was more pronounced in patients with former smoking history, and receiver operating characteristic curve showed that blood Cd had a better-predicting function in patients with MI. Blood Cd levels were significantly related to all-cause mortality in patients with MI, especially in patients with Cd < 1.06 μg/L.
The subject technology is embodied in a method for predicting a delivery rate of a plurality of drugs dispensed by multiple infusion pumps at a delivery point. The method includes receiving one or more operating parameters related to multiple drug pumps and a carrier fluid pump, wherein each of the drug pumps dispenses a drug, and the carrier fluid pump dispenses a carrier fluid. The method also includes determining a delivery rate of a first drug at the delivery point. This can be done by predicting time variation of a concentration of the first drug at the delivery point based on a mathematical model of a mixed flow through a fluid path that terminates at the delivery point. The mixed flow includes the drugs and the carrier fluid. The model includes the operating parameters and a plurality of flow-parameters related to the mathematical model of the mixed flow.
The purpose of this review is to provide a practical guide for the clinical care of patients with acute pancreatitis (AP) from the management of the early phases of disease to the treatment of local complications. AP is one of the most frequent causes of gastroenterological admission in emergency departments. It is characterized by a dynamic and unpredictable course and in its most severe forms, is associated with organ dysfunction and/or local complications, requiring intensive care with significant morbidity and mortality. Initial therapy includes adequate fluid resuscitation, nutrition, analgesia, and when necessary critical care support. In recent years, the development of minimally invasive tailored treatments for local complications, such as endoscopic drainage, has improved patients' acceptance and outcomes. Despite this, the management of AP remains a challenge for clinicians. The present review was conducted by the authors, who formulated specific questions addressing the most critical and current aspects of the clinical course of AP with the aim of providing key messages.
To obtain the subject prophylactic and therapeutic agent containing a specific benzopyran skeleton-containing compound as an active ingredient and exhibiting strong anti-hepatitis C activity based on new action mechanism inhibiting translation step of hepatitis C virus gene.     This prophylactic and therapeutic agent contains a benzopyran skeleton-containing of formula I to formula IV (R<1> to R<26> are each H, OCOCH3 , NO2 , etc.), or its salt as an active ingredient. For example, the compound of formula I is obtained by subjecting ellagic acid extracted from Jussiaea suffruticosa to alkylation of hydroxyl group with an alkylating agent, acylation, etc., of hydroxyl group with a carboxylic acid anhydride. Specifically, e.g. 3,3-di- O-methylellagic acid is exemplified as the compound of formula I. Furthermore, the preventing and treating agent is preferably normally administered at a dialy dose of 1 mg to 5 g/adult in one to several portions.
PROBLEM TO BE SOLVED: To obtain the subject composition improving the itching and dryness of skin after taking a bath, and capable of expressing a good warm touch by including a specific vanillyl alcohol alkyl ether. SOLUTION: This composition contains a vanillyl alcohol alkyl ether of the formula (R<1> is a 1-6C alkyl). One or more kinds of the vanillyl alcohol alkyl ethers may combinedly be added to the composition in a total amount of 0.1-10 wt.%, preferably 0.5-2 wt.%, based on the whole composition. The amount of the composition for each use is preferably determined so that the vanillyl alcohol alkyl ether is contained in bath warm water in an amount of 0.1-500 ppm, especially 0.2-400 ppm. The composition preferably further contains an inorganic salt (e.g. sodium chloride, sodium bicarbonate), an oily component (e.g. an oil or fat, a wax, a hydrocarbon) and the like.
BACKGROUND: Most oncologic patients receiving chemotherapy suffer from neuropathy, which not only severely affects quality of life but also may lead to chemotherapy dose reductions or even discontinuation of cancer therapy. Still, it is difficult to sufficiently control these symptoms with the currently available pharmacological treatments. High tone therapy was reported to be an effective option for neuropathies due to different etiologies. However, to date, there are no studies on high tone therapy in patients with chemotherapy-induced peripheral neuropathy.
METHODS: This randomized, double-blind, and placebo-controlled two-center study was conducted at the Departments of Physical and Rehabilitation Medicine at the Clinics Donaustadt and Ottakring, Vienna, Austria. Patients with histologically verified colorectal carcinoma treated with a platin derivate and neuropathic symptoms were invited to participate. High tone therapy took place in a home-based setting using the HiToP 191 PNP ® or placebo device for three weeks. Neuropathic symptoms and quality of life were assessed via questionnaires. After the follow-up examination, an opt-in was offered to the patients in the placebo group in terms of an open-label treatment with a verum HiToP PNP ® device. In addition, patients with chemotherapy-induced peripheral neuropathy due to various malignant diseases were treated in an open-label setting reflecting a clinical application observation. These patients are reported as a separate group.
RESULTS: In the verum group, there was a significant reduction of paresthesias and mental stress due to paresthesias from baseline until end of therapy, compared to placebo. These findings were observed in the opt-in subgroup, as well. In the open-label clinical application observation group, intensity and mental stress due to paresthesia, pain, cramps, and intensity of tightness/pressure were significantly lower at the end of therapy, compared to baseline.
CONCLUSIONS: Home-based high tone therapy brought about a significant alleviation in paresthesias and mental stress due to paresthesias in the verum but not the placebo group. In the clinical application observation, a significant alleviation in several further neuropathic symptoms was seen.
TRIAL REGISTRATION: This study was registered at clinicaltrials.gov (NCT06048471, 03/02/2020).
The invention relates to a traditional Chinese medical instrumentation, in particular to a Sang-Fu-Teh acupoint pasting film which is simply and conveniently used. In the invention, different traditional Chinese medical ointment can be selected according to diseases to be treated and then applied to a drug storage tank of the pasting film so as to facilitate medical personnel to carry out acupoint application for treating the diseases. The Sang-Fu-Teh acupoint pasting film can facilitate drug replacement in acupoint application, improve working efficiency of Sang-Fu-Teh plaster, reduce working strength and working load of the medical personnel and shorten waiting time of a patient. The Sang-Fu-Teh acupoint pasting film is composed of medical rubber adhesive plaster, the drug storage tank and a covering film; and only the traditional Chinese medical ointment is added to the drug storage tank when in use and then applied to a corresponding acupoint. The Sang-Fu-The acupoint pasting film is used in a Sang-Fu-Teh therapy of the traditional Chinese medical characteristic therapy 'winter disease being cured in summer' and the traditional Chinese medical external therapy such as the Sang-Fu-Teh therapy, common acupoint application and the like. The Sang-Giu-Teh acupoint pasting film has the advantages of convenient use, being safe and reliable, saved time of an operator, low manufacturing cost and easy popularization and application.
In the majority of children with growth hormone (GH) deficiency (GHD), normal GH secretion may occur before the attainment of final height. The aim of the study was to assess the incidence of persistent and transient GHD and the effectiveness of recombined human GH (rhGH) therapy in children with isolated, idiopathic GHD with respect to the moment of therapy withdrawal and according to different diagnostic criteria of GHD. The analysis included 260 patients (173 boys, 87 girls) with isolated, idiopathic GHD who had completed rhGH therapy and who had been reassessed for GH and IGF-1 secretion. The incidence of transient GHD with respect to different pre- and post-treatment criteria was compared together with the assessment of GH therapy effectiveness. The incidence of transient GHD, even with respect to pediatric criteria, was very high. Normal GH secretion occurred before the attainment of near-final height. Application of more restricted criteria decreased the number of children diagnosed with GHD but not the incidence of transient GHD among them. Poor response to GH therapy was observed mainly in the patients with normal IGF-1 before treatment, suggesting that their diagnosis of GHD may have been a false positive. Further efforts should be made to avoid the overdiagnosis GHD and the overtreatment of patients.
The prognosis of AML in elderly patients remain very poor and without significant advances in last decades. AML is a heterogeneous disease in which many altered molecular pathways could contribute to the disease. Thus, curative approaches have been based on highly eradicating regimens using high-dose chemotherapy. However, the low rate of CRs and the high rate of deaths due to toxicity and relapses in elderly patients should stimulate the development of new regimens that overcome these therapeutic obstacles. In recent years, there are a series of new drugs under development that allow the design of sequential combination therapies in this vulnerable population. These drugs have an acceptable toxicity profile and are apparently effective in monotherapy or even in combination, being able to improve the CR rate in this population. The investigators hypothesize that the combination of two targeted drugs that have different mechanisms of action could be capable of breaking the viability of leukemic cells as well as their proliferative qualities, and therefore prolong survival. In this way, the combined action of a pro-apoptotic agent (Venetoclax) and an antiproliferative agent (Quizartinib) could produce a powerful antileukemic effect, preventing the adaptive escape mechanisms of leukemic cells. The investigators have designed a phase I-II trial based on the combination of three drugs regimen LDAC or Azacitidine + Venetoclax + Quizartinib that in this population could be well tolerated by a sequential type administration. The first objective is to achieve rapid control of the disease, using two different schemes, one based in Azacitidine and the other in LDAC, by dose escalation in phase I of the trial. The second goal is to prevent relapse through a maintenance schedule. Phase II will study the efficacy and safety of the recommended dose for Phase II.
An antimicrobial composition includes peracetic acid and witch hazel extract. The peracetic acid can be formed by combining and reacting the acetic acid and hydrogen peroxide, for example at the point of use. Alternatively, the peracetic acid may be formed separately and mixed with the witch hazel extract prior to use. The resulting peracetic acid and hydrogen peroxide and ascetic acid are, thus, combined with the witch hazel extract prior to use. The aqueous combination of peracetic acid, hydrogen peroxide, ascetic acid and witch hazel extract may be applied as an antimicrobial. The antimicrobial composition may be applied topically to interior and/or exterior of various organs [i.e. skin, nose, ears, mouth, throat, urethra, urinary bladder, gastro-intestinal organs] or instilled through an indwelling urinary catheter or applied or inserted as a topical additive or coating to devices on other organ surfaces or other medical devices, or on the skin of the body or surfaces of inanimate objects.
OBJECTIVE: This study aimed to examine the interactions between ultraprocessed food (UPF) consumption and genetic predisposition with the risk of gout.
METHODS: This prospective cohort study analysed 181 559 individuals from the UK Biobank study who were free of gout at baseline. UPF was defined according to the NOVA classification. Assessment of genetic predisposition for gout was developed from a genetic risk score of 33 single nucleotide polymorphisms. Cox proportional hazards were used to estimate the associations between UPF consumption, genetic predisposition and the risk of gout.
RESULTS: Among the 181 559 individuals in the study, 1558 patients developed gout over 1 648 167 person-years of follow-up. In the multivariable adjustment model, compared with the lowest quartile of UPF consumption, the hazard ratio (HR) and 95% CI of the highest UPF consumption was 1.16 (1.01, 1.33) for gout risk, and there was a non-linear correlation between UPF consumption and the development of gout. In substitution analyses, replacing 20% of the weight of UPF in the daily intake with an equal amount of unprocessed or minimally processed food resulted in a 13% lower risk of gout (HR: 0.87; 95% CI: 0.79, 0.95). In the joint-effect analysis, the HR (95% CI) for gout was 1.90 (1.39, 2.60) in participants with high genetic predisposition and high UPF consumption, compared with those with low genetic predisposition and low UPF consumption.
CONCLUSION: In summary, UPF consumption was found to be associated with a higher risk of gout, particularly in those participants with genetic predisposition to gout. Our study indicated that reducing UPF consumption is crucial for gout prevention.
A drug carrier composition comprising a drug complexed with dermatan sulfate is disclosed. The drug is preferably an antitumor drug and may be taxol, a peptide onco-agent or vincristine. The most preferred antitumor drug is doxorubicin. The dermatan sulfate is essentially purified dermatan sulfate with a sulfur content of up to 9 % (w/w) and with selective oligosaccharide oversulfation. The compositions are administered in a fashion that allows efficient vascular access and induced the following in vivo effects: 1) rapid, partial or total endothelial envelopment of the drug (diagnostic) carrier; 2) sequestration of the carrier and protection of the entrapped agent from blood vascular clearance at an early time (2 minutes) when the endothelial pocket which envelops the carrier still invaginates into the vascular compartment; 3) acceleration of the carrier's transport across and/or through the vascular endothelium or subendothelial structures into the tissue compartment (intestitium); and 4) improvement of the efficiency with which the drug migrates across the endothelium, or epi-endothelial or subendothelial barriers, such that a lower total drug dose is required to obtain the desired effect relative to that required for standard agents. Analogous tissue uptake is described for transepithelial migration into the lungs, bladder and bowel.
Epidural catheter: Bupivacain 1,0 mg/ml + Fentanyl 2 micrograms/ml. Oral analgesia: Paracetamol, NSAID and placebo tablets.
INTRODUCTION: Faced to the growing development of collecting systematic molecular analyses in relapsed pediatric cancers to transform their targeted matched therapies, this study aimed to assess the clinical and therapeutic indications of systematic diagnostic genomic explorations performed in pediatric solid cancers to determine which type of screening and if it afford at relapse time an accurate targeted strategy.
METHODS: A total of 280 patients less than 22 years, referred at the University Hospitals of Strasbourg for a newly diagnosed solid tumor from January 2015 to December 2021, were prospectively genomically investigated since diagnosis. Using 7 different molecular tests going from single-gene methods (IHC, FISH, RT-PCR, Sanger sequencing, droplet digital PCR) to largescale analyses (Next-Generation sequencing, RNAsequencing and FoundationOne®CDx), we explored retrospectively the molecular findings in those pediatric solid tumors (except hematolymphoid cancers) to improve diagnosis, prognosis assessment and relapse therapeutics.
RESULTS: One hundred and ninety-eight patients (71%) underwent molecular biology (MB) at diagnosis. Thirty-eight different histologies were grouped into cerebral tumors (30%), sarcomas (26%, bone and soft tissues), various blastomas (27%), and other entities (17%). Over a median 40-month follow-up, the overall survival rate of patients was 85% and the relapse rate 28%. Of the 326 analyses carried out, 245 abnormalities (single nucleotide variations: 50%, fusions: 25%, copy number alteration: 20%) concerning 70 oncogenes were highlighted. The overall clinical impact rate was 84%. Broad-spectrum analyses had a higher therapeutic impact (57%) than the targeted analyses (28%). 75% of broad-spectrum tests found an actionable variant conducting 23% of patients to receive rapidly a matched targeted therapy since first relapse.
CONCLUSION: Our experience highlighted the clinical utility of molecular profiling of solid tumors as soon as at diagnosis in children to expect improving access to innovative agents at relapse.
PURPOSE: A curing composition containing L-arginine, Lycii Fructus extract, Eucommiae Cortex extract for impotency is provided, which shows good curing effect to impotency without side-effect. CONSTITUTION: The curing composition for impotency comprises of L-arginine crystalline powder 5-200wt. part, Eucommiae Cortex extract containing 0.02-0.12% of genipocidic aid 5-15wt. part, Lycii Fructus extract(solid part is over 65%) 10-30wt. part. The composition shows enhanced living body activity effect by adding vitamin B, C, E, pantothenic acid or folic acid, which can be prepared in the form of solution, suspension, tablets, capsules, soft capsules, pills or granules. A process for the preparation of Eucommiae Cortex extract comprises of: cutting the Eucommiae Cortex into fine pieces, and pouring into distilled water 10L; boiling for 3hrs in water bath, and filtering after cooling; concentrating the residual solution to get the genipodic acid contained powder. A process for the preparation of Lycii Fructus extract comprises of: cutting the Lycii Fructus into fine pieces, and pouring into distilled water 5L; boiling for 3hrs in water bath, and filtering after cooling; and concentrating the residual solution to get the solid powder.
In China, the first-line therapy to treat Helicobacter pylori (Hp) consists of a bismuth-based proton pump inhibitor (PPI) and two antibiotics for 14 days.But, eradication has become less successful due to low compliance and high resistance to antibiotics. Therefore, it is necessary to develop new treatment strategies that increase the eradication rate and reduce adverse effects. Vonoprazan is a novel potassium-competitive acid blocker more effective in suppressing acid production than proton pump inhibitors (PPIs). Several studies previously suggested that vonoprazan containing antibiotic therapy was superior to other PPI-containing therapies for Hp. Most strains of Helicobacter pylori are sensitive to amoxicillin. Bismuth salts, a topical agent, which are available in our country, have a synergistic effect on antibiotics and decrease the bacterial load. Therefore, the investigators performed a prospective, multi-center, randomized trial, to investigate the efficacy of Triple Therapy with Vonoprazan, Amoxicillin, and Bismuth for eradication of Hp, compared with standard quadruple therapy.